Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (MIRA), a preclinical-stage pharmaceutical development company, filed this Form 8-K on December 10, 2024. The filing reports the successful completion of a current Good Laboratory Practice (GLP) preclinical safety program for its novel oral ketamine analog, Ketamir-2.
Key Financial Metrics
This filing is a Current Report (Item 8.01 Other Events) and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Operational Milestones
The primary material event is the validation of Ketamir-2's safety profile with no adverse findings. Key study results include:
- Cardiovascular Safety: No adverse effects noted in dogs at therapeutic doses.
- CNS Assessment: No significant changes in rats at therapeutic doses; high-dose effects were transient.
- Respiratory Safety: No effects noted in rats across all tested doses.
- Toxicology: Well-tolerated in dogs at daily doses up to 200 mg/kg with no observed adverse effects.
- Mutagenicity: Ames Test confirmed Ketamir-2 is non-mutagenic.
Guidance, Outlook, and Risks
Outlook and Timeline:
- The Company plans to submit an Investigational New Drug (IND) application by the end of 2024.
- Phase I clinical trials are scheduled to initiate in the first quarter of 2025.
- Early data from Phase I trials, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamics for neuropathic pain and psychosis, is expected by the second quarter of 2025.
Risks and Contingencies:
- The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks beyond the Company's control.
- Further details on risks are referenced in the Annual Report on Form 10-K for the year ended December 31, 2023.
Investor Verification Checklist
- Confirm the actual submission date of the IND application for Ketamir-2 by year-end 2024.
- Verify the initiation of Phase I clinical trials in Q1 2025.
- Review the Company's cash position and runway in the most recent 10-K or 10-Q to assess funding sufficiency for upcoming clinical trials.
- Monitor for any regulatory feedback or delays following the anticipated IND submission.